Home > Resources > Whitepapers > mRNA Vaccines: Disruptive Innovation in Vaccination

mRNA Vaccines: Disruptive Innovation in Vaccination

May 25, 2017

Vaccines to prevent infectious diseases are the greatest medical innovation of all time. The CDC estimates that U.S. childhood vaccinations given in the past two decades will prevent Americans from 322 million illnesses, 21 million hospitalizations, 732,000 deaths, $295 billion of direct costs, and $1.3 trillion in social costs. For example, before the advent of the measles vaccine in 1963, the virus infected 500,000 Americans annually, causing 480,000 hospitalizations. Today, we see only 60 measles cases a year, primarily from foreign travelers. Smallpox, polio, diphtheria, pertussis, measles, mumps, and many other vaccines have also had an enormous impact on public health.

Spotlight

Ceres, Inc.

Ceres, Inc. is an agricultural biotechnology company that develops and markets seeds and traits to produce crops for feed, forages, sugar and other markets.

OTHER WHITEPAPERS

Three Trends to Watch in Life Sciences

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations